Guidance for Industry: Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees
Extension without change of a currently approved collection
No
Regular
Approved without change
12/09/2015
09/22/2015
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
12/31/2018
36 Months From Approved
12/31/2015
1,185
0
1,185
1,795
0
1,795
0
0
0
The collection of information includes the following reporting, recordkeeping, and third-party disclosure provisions for sponsors and data monitoring committees (DMCs): (1) Sponsor reporting to FDA on DMC recommendations related to safety; (2) standard operating procedures (SOPs) for DMCs; (3) DMC meeting records; (4) sponsor notification to the DMC regarding waivers; and (5) DMC reports of meeting minutes to the sponsor.
The submission of the requested information provides the appropriate parties with essential information regarding the clinical trial upon which they may base their recommendations. The SOPs ensure that established written procedures are followed and proper recordkeeping is performed.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.